Introduction
============

Duodenal ulcer (DU) is a defect in the duodenal wall that extends through the muscularis mucosa into the deeper layers (Editorial Board of Chinese Journal of Digestion, 2016). A systematic review ([@B49]) estimated that the pooled incidence rate of uncomplicated DU, DU bleeding, and perforated DU was 0.510 (95% confidence interval: 0.380--0.670), 0.240(0.190--0.300), and 0.055 (0.038--0.079) per 1,000 person-years, respectively. The prevalence of DU reported in recent population-based studies varied greatly in different countries: 2.1% in Sweden ([@B4]), 3.9% in Italy ([@B87]), 5.6% in Northern Saudi Arabia ([@B2]), 7.4% in Bangladesh ([@B25]), and 13.3% in China ([@B47]), respectively.

Although eradication of *Helicobacter pylori* (Hp) is associated with higher healing rates and lower ulcer recurrence rates in patients with Hp-positive DU ([@B43]; [@B23]), non-eradication therapies are still appropriate for the patients with Hp-negative DU or without the result of Hp testing. Pump proton inhibitors (PPIs) are a kind of benzimidazole prodrug that inhibit gastric acid secretion by irreversibly binding to the hydrogen-potassium ATPase pump residing on the luminal surface of the parietal cell membrane ([@B80]; [@B67]). These agents have been recommended by the Japanese Society of Gastroenterology (JSG) as first-line treatment for the initial non-eradication treatment of DU ([@B65]). Chinese guidelines recommended the standard dose of PPI given over 4--6 weeks for the treatment of DU (Editorial Board of Chinese Journal of Digestion, 2016). Omeprazole (OME; 20 mg/day), lansoprazole (LAN; 30 mg/day), pantoprazole (PAN; 40 mg/day), rabeprazole (RAB; 20 mg/day), ilaprazole (ILA; 10 mg/day), and esomeprazole (ESO; 20 mg/day) are widely used PPIs in the initial non-eradication treatment of DU. PPIs differ in their pKa, bioavailability, peak plasma levels, and route of excretion. A previous network meta-analysis ([@B34]) of randomized controlled trials (RCTs) compared the healing rates and adverse effects of different PPIs in ordinary doses for patients with DU and concluded there was no significant difference for the efficacy and tolerance between the ordinary doses of PPIs. However, this study included 24 RCTs and compared nine interventions, which resulted in an underpowered test. Moreover, ranitidine (RAN) and famotidine (FAM) were considered one intervention (H~2~RA), which introduced clinical heterogeneity to the model. Therefore, this conclusion needs to be further verified. On the other hand, cost-effectiveness among PPIs is still controversial due to high variability in cost. The present study aims to evaluate the efficacy, safety, and cost-effectiveness of standard-dose PPI medications in the initial non-eradication treatment of DU.

Materials and Methods {#s1}
=====================

We followed the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). The systematic review was prospectively registered on International Prospective Register of Systematic Review (PROSPERO, CRD42017079704). The economic evaluation reporting also followed the Consolidated Health Economic Evaluation Reporting Standards Statement (CHEERS) (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}).

Search
------

PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched using the search strategies detailed in Supplementary Table [S3](#SM1){ref-type="supplementary-material"}, from their inception to September 2017. Clinicaltrials.gov also was searched using the terms "duodenal ulcer," "proton pump inhibitor," "omeprazole," "pantoprazole," "lansoprazole," "rabeprazole," "ilaprazole," "esomeprazole," "famotidine," and "ranitidine." The China National Knowledge Infrastructure (CNKI), VIP database, and Wanfang database were also searched with Chinese terms. We reviewed the references from published network meta-analyses of PPIs, included studies, and relevant review articles to find additional studies.

Eligibility Criteria
--------------------

We included studies meeting the following criteria: (1) RCTs; (2) participants with endoscopically verified DU; (3) a focus on the following interventions by oral administration: OME 20 mg/day, PAN 40 mg/day, LAN 30 mg/day, RAB 20 mg/day, ILA 10 mg/day, ESO 20 mg/day, RAN 300 mg/day, FAM 40 mg/day, and placebo (PLA); (4) the duration of treatment should be 4 weeks or longer; (5) Reporting on any of the following outcomes: 4-week ulcer healing rate (4-UHR, primary outcome), defined as complete re-epithelialization of the ulcer crater irrespective of residual erosions after 4 weeks of treatment; incidence of overall adverse events (AEs, secondary outcome); and (6) published in English or Chinese.

We excluded studies that enrolled participants with upper gastrointestinal bleeding, stress ulcer, or the concomitant therapy for Hp eradication, studies compared only different doses of the same drug, and studies reported as in-conference abstracts, which were impossible to assess the risk of bias.

Study Selection and Data Extraction
-----------------------------------

Two reviewers independently screened the titles and abstracts of all studies identified by the search strategies according to the inclusion criteria. The full-texts of all potentially relevant articles were downloaded for further reviewing. We resolved any disagreements through discussion or adjudication by a third reviewer (Juan Xie).

We used a pre-designed data collection form to extract data from each eligible study, including: (1) authors, year of publication, country or region where the study conducted; (2) study design; (3) medication used in treatment or control group, dose, and duration of treatment; (4) number of participants randomized into each group; (5) diagnosis, gender, age, smoking and drinking habits of participants; (6) length of follow up; (7) outcome data (outcomes of interest, events and number of patients included for analyses in each group); and (8) sources of funding. As to the outcome data, we extracted intention-to-treat (ITT) data where these were reported. Otherwise, we extracted the data as reported (often a modified ITT based on, e.g., all patients who received at least one dose of the study drug). A kappa statistic (K) was manually calculated to measure the agreement between two reviewers on the decisions made in study selection.

Risk of Bias Assessment
-----------------------

Two reviewers independently assessed the risk of bias in each included study using the tool developed by Cochrane Collaboration ([@B31]). The items included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other bias. We categorized the judgments as low, high, or unclear risk of bias and created a summary graph using Review Manager Software (version 5.3).

Statistical Synthesis
---------------------

We generated network plots of comparisons to illustrate which interventions had been compared within randomized trials (head-to-head comparisons). A Bayesian random effects network meta-analysis was conducted to compare the relative efficacy (4-UHR) and safety (the incidence of AEs) between different regimens. WinBUGS (version 1.4.3) was used to perform the analysis. Posterior samples were generated using Markov Chain Monte-Carlo (MCMC) simulation in two parallel chains. We used 5,000 burn-in iterations to allow convergence, and then a further 50,000 iterations to produce the outputs. We calculated odds ratios (ORs) with 95% confidence intervals (95% CIs), and a surface under the cumulative ranking (SUCRA). We evaluated and graded the statistical heterogeneity according to the value of *I*^2^. A value for *I*^2^ of 50% or greater was used to denote significant heterogeneity. A node-splitting approach employed to assess inconsistency in the triangular loop ([@B73]) using the gemtc package in the R environment (version 3.3.1) ([@B74]). In order to observe the robustness of results, we conducted sensitivity analysis to compare the results from ITT data to per-protocol (PP) data. We also conducted a sensitive analysis by excluding trials with high risk of bias. Subgroup analyses were also conducted between Chinese and non-Chinese participants. Patients from Chinese Mainland, Hong Kong and Taiwan were considered to be Chinese for this study.

Cost-Effectiveness Analysis
---------------------------

We evaluated the cost-effectiveness of PPIs in Chinese patients with DU from the payer's perspective. A decision tree model was constructed in Excel to explore the economic benefits and Quality-Adjusted Life Year (QALY) gains. The model considered costs and outcomes over 1 year, and was based on 10000 Chinese DU patients (male/female = 1), one each in the OME, PAN, LAN, RAB, ILA, and ESO arms. To estimate the probability of 4-UHR for OME, we conducted a single arm meta-analysis based on data from trials on OME with a random-effect model using the meta package in the R environment (version 3.3.1) ([@B19]). Then the probability for OME and the OR for 4-UHR for each PPI versus OME as estimated in the NMA were employed to produce the respective probabilities for other PPIs. To estimate QALYs, we extracted the data about health state utility value from previously published research ([@B27]; [@B69]). The cost of each treatment strategy was calculated according to the drug cost for one standard treatment (4 weeks) obtained from the National Health and Family Planning Commission of the People's Republic of China^[1](#fn01){ref-type="fn"}^. The costs of managing AEs were obtained from the published literature ([@B85]), while all other costs associated with administering the medications were assumed to be the same across the five arms. All costs were recorded in Chinese yuan and then converted into US dollars (exchange rate: 1 yuan = \$0.1591). The incremental cost-effectiveness ratio (ICER) per additional life-years saved was calculated to compare the performance of different PPIs. We considered treatment strategies with an ICER of less than \$25,761 (i.e., 3-times Chinese gross domestic product \[GDP\] ([@B38]) per capita in 2016^[2](#fn02){ref-type="fn"}^) per QALY saved to be acceptable. Probabilistic sensitivity analysis (PSA) was performed to test the robustness of the model.

Results
=======

Search Result and Characteristics of Included Studies
-----------------------------------------------------

A total of 7,137 citations were obtained from the literature search (*K* = 0.9). Figure [1](#F1){ref-type="fig"} showed the selection process. Sixty-two RCTs ([@B5]; [@B68]; [@B6]; [@B56]; [@B20]; [@B55]; [@B3]; [@B10]; [@B37]; [@B61]; [@B26]; [@B57]; [@B51]; [@B54]; [@B72]; [@B18]; [@B33]; [@B41]; [@B52]; [@B75], [@B79], [@B77], [@B76]; [@B1]; [@B71]; [@B30]; [@B60]; [@B88]; [@B40]; [@B42]; [@B44], [@B45], [@B46]; [@B64]; [@B9]; [@B16]; [@B22]; [@B63]; [@B66]; [@B81]; [@B14]; [@B29]; [@B17]; [@B8]; [@B59]; [@B62]; [@B13]; [@B35]; [@B70]; [@B83], [@B84]; [@B28]; [@B86]; [@B32]; [@B36]; [@B50]; [@B90]; [@B78]; [@B89]; [@B48]; [@B12]; [@B11]) with 10,339 participants were included in the network meta-analysis ([@B46]). As shown in Supplementary Table [S4](#SM1){ref-type="supplementary-material"}, included trials were conducted in 27 countries or regions (e.g., Australia, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, Iceland, India, Ireland, Israel, Italy, Karachi, Malaysia, Netherlands, Philippines, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, and the United States). There were 39 trials published in English and 23 trials published in Chinese, respectively. Among the included trials, 60 were two-arm studies and 2 were three-arm studies, with a total of eight different interventions (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). No study regarding ESO was included according to the inclusion and exclusion criteria (e.g., studies reported as in-conference abstracts, studies with the concomitant therapy for Hp eradication, or studies for gastric ulcer). The baseline characteristics of the participants were shown in Supplementary Table [S4](#SM1){ref-type="supplementary-material"}. The age of participants was ranged from 16 to 85 years old, and the proportion of males was ranged from 43.33 to 92.79%. Thirty-eight studies reported the number of smokers (28.13--72.46%). Twenty-eight studies reported the number of participants drinking alcohol (0.90--68.19%). The duration of treatment ranged from 4 to 8 weeks.

![Flow diagram of study selection process for this systematic review.](fphar-09-01512-g001){#F1}

![Network of included RCTs with available direct comparisons for 4-week ulcer healing rate. The widths of the lines indicate the number of included trials.](fphar-09-01512-g002){#F2}

![Network of included RCTs with available direct comparisons for adverse events. The widths of the lines indicate the number of included trials.](fphar-09-01512-g003){#F3}

Risk of Bias Assessment
-----------------------

As shown in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}, four studies ([@B18]; [@B64]; [@B59]; [@B35]) had low risk of selection bias for clearly describing the methods of randomization and allocation concealment, while the other 58 were unclear because the information about selection participants was not reported. Thirty-nine studies (62.90%) had low risk of performance bias and detection bias, as both participants and study personnel were masked; however, this risk was not clear in 23 studies (37.10%) for failing to report who was blinded. Sixty-one studies (98.39%) had low risk of attrition bias, as there was no loss to follow-up or missing data was appropriately addressed (e.g., applying ITT analysis which could underestimate the efficacy of the intervention). Thirty-nine studies (62.90%) had low risk of reporting bias since they had reported all predesigned outcomes. The other 23 studies (37.10%) neither mentioned registration information nor had an available protocol, so it was unclear whether all the pre-designed outcomes in these studies had been reported. Eight studies (12.90%) were supported by pharmaceutical industry, and bias caused by conflict of interest was unclear.

Four-Week Ulcer Healing Rate (4-UHR)
------------------------------------

The 4-UHR was reported in 62 studies including 10,339 patients. There was no substantial heterogeneity among studies across most comparisons (*I*^2^\< 50%), with the exception of RAN vs. PAN (*I*^2^= 59.5%) (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). Inconsistency was not detected across all comparison groups (*P* \> 0.05) (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). Table [1](#T1){ref-type="table"} showed that all the PPIs significantly improved healing rates compared to H~2~RAs and PLA, while there was no significant difference among PPIs. The probability of each regimen to be the most superior was shown in Supplementary Table [S5](#SM1){ref-type="supplementary-material"}, which indicated that ILA (SUCRA = 1.0, 95% CI: 0.7143--1.0), PAN (SUCRA = 0.8571, 95% CI: 0.5714--1.0), RAB (SUCRA = 0.5714, 95% CI: 0.4286--1.0), OME (SUCRA = 0.5714, 95% CI: 0.4286--0.8571), and LAN (SUCRA = 0.4286, 95% CI: 0.4286--0.8571) were the top five regimens, respectively.

###### 

Odds ratio of various PPIs from the network meta-analysis for 4-week ulcer healing rate (intention-to-treat data).

  OR    OME                      PAN                      LAN                      RAB                      ILA                      RAN                     FAM                     PLA
  ----- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ ----------------------- ----------------------- -----------------------
  OME   1.0                      11.241 (0.942, 1.655)    10.900 (0.634, 1.268)    10.988 (0.596, 1.638)    11.463 (0.994, 2.185)    10.420 (0.348, 0.511)   10.328 (0.254, 0.424)   10.152 (0.093, 0.258)
  PAN   10.806 (0.604, 1.064)    1.0                      10.721 (0.477, 1.091)    10.802 (0.457, 1.366)    11.181 (0.732, 1.922)    10.339 (0.259, 0.441)   10.265 (0.189, 0.371)   10.121 (0.072, 0.219)
  LAN   11.110 (0.789, 1.576)    11.386 (0.917, 2.099)    1.0                      11.110 (0.615, 1.960)    11.648 (0.989, 2.702)    10.471 (0.331, 0.650)   10.366 (0.251, 0.536)   10.170 (0.099, 0.303)
  RAB   11.013 (0.611, 1.677)    11.247 (0.732, 2.188)    10.901 (0.510, 1.626)    1.0                      11.457 (0.801, 2.859)    10.421 (0.261, 0.694)   10.334 (0.192, 0.563)   10.153 (0.083, 0.282)
  ILA   10.684 (0.458, 1.006)    10.847 (0.520, 1.366)    10.607 (0.370, 1.012)    10.686 (0.350, 1.248)    1.0                      10.288 (0.185, 0.445)   10.225 (0.138, 0.358)   10.103 (0.055, 0.199)
  RAN   12.381 (1.958, 2.876)    12.949 (2.265, 3.860)    12.122 (1.539, 3.024)    12.375 (1.440, 3.841)    13.472 (2.248, 5.416)    1.0                     10.780 (0.621, 0.994)   10.359 (0.221, 0.614)
  FAM   13.052 (2.359, 3.940)    13.773 (2.694, 5.302)    12.729 (1.867, 3.979)    12.993 (1.777, 5.201)    14.440 (2.794, 7.243)    11.281 (1.006, 1.611)   1.0                     10.455 (0.270, 0.815)
  PLA   16.599 (3.877, 10.770)   18.261 (4.565, 13.940)   15.891 (3.306, 10.150)   16.518 (3.549, 12.050)   19.709 (5.028, 18.250)   12.787 (1.630, 4.519)   12.197 (1.227, 3.701)   1.0
                                                                                                                                                                                     

Each number is an odds ratio (=row/column), and 95% confidence interval. OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; RAN, ranitidine, 300 mg/day; FAM, famotidine, 40 mg/day; PLA, placebo. Green shading: no significant difference; red shading: significant difference.

Incidence of AEs
----------------

Fifty studies (9,012 participants) reported the overall incidence of any AEs in participants receiving the eight interventions. The heterogeneity (Supplementary Figure [S4](#SM1){ref-type="supplementary-material"}) was not statistically significant among most comparisons (*I*^2^\< 50%), except for PAN vs. LAN (*I*^2^= 51.8% for network). The inconsistency (Supplementary Figure [S5](#SM1){ref-type="supplementary-material"}) was also not statistically significant among most triangular loops with exception of PAN vs. OME (*P* = 0.0359). As shown in Table [2](#T2){ref-type="table"}, there was no significant difference for the incidence of AEs among all the PPIs, H~2~RAs, and PLA. The results of SUCRA (Supplementary Table [S5](#SM1){ref-type="supplementary-material"}) indicated that the relative ranking of preferred agents for safety was: ILA (0.8571, 95% CI: 0.2857--1.0), RAB (0.8571, 95% CI: 0.0--1.0), LAN (0.5714, 95% CI: 0.1429--1.0), FAM (0.5714, 95% CI: 0.0--1.0), OME (0.4286, 95% CI: 0.1429--0.8571), RAN (0.4286, 95% CI: 0.1429--0.8571), PAN (0.2857, 95% CI: 0.0--0.8571), PLA (0.0, 95% CI: 0.0--0.8571). The most common AEs included headache, diarrhea, nausea, rash, vomiting, dizziness, constipation, and myalgia (Table [3](#T3){ref-type="table"}). Most AEs were mild, transient, and reversible.

###### 

Odds ratio of various PPIs from the network meta-analysis for adverse events.

  OR    OME                     PAN                     LAN                     RAB                     ILA                     RAN                     FAM                     PLA
  ----- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------------------------
  OME   1.0                     11.074 (0.720, 1.602)   10.905 (0.618, 1.366)   10.778 (0.390, 1.465)   10.711 (0.440, 1.105)   10.983 (0.748, 1.281)   10.895 (0.565, 1.432)   11.659 (0.714, 3.676)
  PAN   10.931 (0.624, 1.390)   1.0                     10.844 (0.511, 1.437)   10.732 (0.328, 1.543)   10.661 (0.363, 1.186)   10.915 (0.621, 1.334)   10.834 (0.474, 1.480)   11.548 (0.6176, 3.669)
  LAN   11.105 (0.732, 1.619)   11.185 (0.696, 1.957)   1.0                     10.865 (0.381, 1.770)   10.780 (0.430, 1.386)   11.079 (0.701, 1.612)   10.982 (0.598, 1.614)   11.821 (0.724, 4.295)
  RAB   11.285 (0.683, 2.564)   11.366 (0.648, 3.045)   11.157 (0.565, 2.622)   1.0                     10.915 (0.417, 2.078)   11.261 (0.636, 2.658)   11.142 (0.528, 2.660)   12.130 (0.746, 6.160)
  ILA   11.406 (0.905, 2.276)   11.512 (0.844, 2.753)   11.282 (0.722, 2.327)   11.093 (0.481, 2.397)   1.0                     11.389 (0.819, 2.355)   11.261 (0.665, 2.420)   12.350 (0.911, 5.847)
  RAN   11.017 (0.781, 1.338)   11.093 (0.750, 1.610)   10.927 (0.620, 1.427)   10.793 (0.376, 1.573)   10.720 (0.425, 1.221)   1.0                     10.910 (0.601, 1.428)   11.683 (0.720, 3.876)
  FAM   11.117 (0.698, 1.770)   11.199 (0.676, 2.110)   11.018 (0.620, 1.672)   10.876 (0.376, 1.893)   10.793 (0.413, 1.503)   11.098 (0.700, 1.664)   1.0                     11.849 (0.705, 4.521)
  PLA   10.603 (0.272, 1.401)   10.646 (0.273, 1.620)   10.549 (0.233, 1.381)   10.470 (0.162, 1.342)   10.426 (0.171, 1.098)   10.594 (0.258, 1.389)   10.541 (0.221, 1.419)   1.0
                                                                                                                                                                                

Each number is an odds ratio (=row/column), and 95% confidence interval. OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; RAN, ranitidine, 300 mg/day; FAM, famotidine, 40 mg/day; PLA, placebo. Green shading: no significant difference.

###### 

The incidence of adverse events for different intervention.

  Adverse events                OME    PAN    LAN    RAB    ILA    RAN    FAM    PLA
  ----------------------------- ------ ------ ------ ------ ------ ------ ------ ------
  Headache (%)                  2.57   1.79   1.88   3.49   0.46   2.70   3.20   4.21
  Diarrhea (%)                  1.58   1.54   1.16   2.30   1.83   1.70   1.14   3.92
  Nausea (%)                    2.14   1.02   1.73   0.53   NR     0.88   1.90   3.92
  Rash (%)                      1.01   1.10   1.60   1.47   NR     0.76   0.92   NR
  Vomiting (%)                  0.25   NR     NR     0.53   2.02   0.57   1.11   3.92
  Dizziness (%)                 1.52   2.05   1.05   NR     NR     0.81   0.84   NR
  Constipation (%)              0.18   0.80   2.21   NR     NR     0.63   1.32   NR
  Myalgia                       0.84   0.48   1.05   0.53   NR     0.59   NR     NR
  Loss of appetite (%)          2.36   NR     1.82   NR     2.11   NR     1.17   NR
  Insomnia (%)                  1.09   2.50   1.82   NR     NR     NR     0.84   NR
  Dry mouth (%)                 2.37   2.17   0.80   NR     NR     NR     1.27   NR
  Psychiatric disorder (%)      2.84   NR     0.42   NR     NR     1.85   1.41   NR
  Cardiovascular disorder (%)   0.33   NR     0.57   0.53   NR     0.84   NR     NR
  Asthenia (%)                  2.77   NR     2.87   NR     NR     0.44   NR     NR
  Somnolence (%)                1.12   NR     NR     NR     NR     1.22   0.78   NR
  Abdominal distension (%)      1.58   NR     NR     NR     NR     1.91   2.20   NR
  Abnormal liver function (%)   1.23   1.02   NR     NR     3.63   NR     NR     NR
  Renal impairment (%)          0.19   NR     NR     NR     1.45   0.94   NR     NR
                                                                                 

NR, not reported. OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; RAN, ranitidine, 300 mg/day; FAM, famotidine, 40 mg/day; PLA, placebo.

Sensitivity Analyses
--------------------

Sensitivity analyses comparing data from ITT populations to PP populations were presented in Table [1](#T1){ref-type="table"} and Supplementary Table [S6](#SM1){ref-type="supplementary-material"}, and analyses based on data from trials with lower risk of bias were shown in Supplementary Tables [S7](#SM1){ref-type="supplementary-material"}, [S8](#SM1){ref-type="supplementary-material"}, which showed similar results for both outcomes.

Subgroup Analyses
-----------------

Considering the impact of ethnicity on the results, we performed subgroup analyses in Chinese and non-Chinese participants, respectively. As shown in Supplementary Tables [S9](#SM1){ref-type="supplementary-material"}, [S10](#SM1){ref-type="supplementary-material"}, ILA tended to be more effective in improving 4-UHR in Chinese compared to non-Chinese participants. Chinese and non-Chinese subgroups showed similar results for incidence of AEs (Supplementary Tables [S11](#SM1){ref-type="supplementary-material"}, [S12](#SM1){ref-type="supplementary-material"}).

Cost-Effectiveness Results
--------------------------

Table [4](#T4){ref-type="table"} and Supplementary Figure [S6](#SM1){ref-type="supplementary-material"} presented the base-case results for a duration of 1 year: OME had the lowest expected total cost (\$53023.30) for 10,000 Chinese patients with DU, followed by PAN, LAN, RAB, and ILA. ILA had the highest expected quality adjusted life years (QALYs) (8110.18), followed by RAB, PAN, LAN, and OME. OME was used as the baseline in calculating the ICERs of other strategies. The ICERs for PAN, LAN, RAB, and ILA relative to OME corresponded to \$5134.67 per QALY, \$17801.67 per QALY, \$25488.31 per QALY, and \$44572.22 per QALY, respectively. In the present cohorts, ILA was associated with the best efficacy with respect to incremental QALYs but it also had the highest costs. PAN, LAN, and RAB were also associated with greater efficacy but higher costs than OME. According to the threshold recommended by WHO, PAN was preferred based on its efficacy at an acceptable cost. Nevertheless, ILA was found not to be a strongly recommended treatment for patients in China, since the ICER corresponded to higher than \$25683.33.

###### 

Cost-effectiveness of PPIs for treatment of duodenal ulcer patients.

  Treatment strategy   Cost (US\$)   Incremental cost (US\$)   QALYs     Incremental QALYs   ICER
  -------------------- ------------- ------------------------- --------- ------------------- ----------
  OME                  53023.30      NA                        8077.61   NA                  NA
  PAN                  126543.21     73519.91                  8091.93   14.32               5134.67
  LAN                  304323.48     251300.18                 8091.72   14.12               17801.67
  RAB                  430823.73     377800.43                 8092.43   14.82               25488.31
  ILA                  1504703.48    1451680.18                8110.18   32.57               44572.22
                                                                                             

QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio, Calculated as the average cost per patient and the average number of QALYs per patient in this strategy minus those of the treatment of OME; OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; NA, not applicable.

Probabilistic sensitivity analyses (Supplementary Table [S13](#SM1){ref-type="supplementary-material"}) with 1,000 Monte Carlo simulations revealed that PAN, LAN, RAB, and ILA had probabilities of 73.1% (Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}), 60.6% (Supplementary Figure [S9](#SM1){ref-type="supplementary-material"}), 60.9% (Supplementary Figure [S10](#SM1){ref-type="supplementary-material"}), 15.2% (Supplementary Figure [S11](#SM1){ref-type="supplementary-material"}), respectively, of being cost-effective relative to OME under the threshold (\$25683.33) currently accepted in China.

Discussion
==========

To our best knowledge, this is the first systematic review incorporating a network meta-analysis and cost-effectiveness analysis to compare PPIs for the initial non-eradication treatment of DU, and recommend a rank order based on efficacy, safety, and cost. Our study suggests that all the PPIs significantly improve the 4-UHR compared to H~2~RAs and PLA, while there is no significant difference for 4-UHR among PPIs. The incidences of AEs of PPIs, H~2~RAs, and PLA are similar during 4-week follow-up. PAN seems to be the most cost-effective choice in the initial non-eradication treatment of DU in China.

Most guidelines recommended that all patients with peptic ulcers should be tested for infection with Hp and treated ([@B53]). Nevertheless, an overview of systematic reviews and network meta-analysis ([@B82]) concluded that triple therapy with different antibiotics would influence the eradication rate which was associated with healing rate. In order to reduce the clinical heterogeneity caused by different antibiotics, this review evaluated the efficacy, safety, and cost-effectiveness of different PPIs in the non-eradication treatment of DU. At present, there are six PPIs (OME, PAN, LAN, RAB, ESO, and ILA) in the pharmaceutical market, but only five PPIs were included in this study. The main reason was that the ESO was more effective in the inhibition of gastric acid secretion ([@B7]; [@B58]) and utilized more for the eradication of Hp, instead of non-eradication treatment of DU.

The subgroup analyses suggested that ILA obtained much better efficacy in Chinese rather than non-Chinese. The reason could be attributed to the fact that most RCTs including ILA were conducted in China, and one RCT ([@B11]) with high risk of bias reported extremely high 4-UHR of ILA in Chinese. After excluding that RCT, there was no significantly difference in the 4-UHR between ILA and other PPIs irrespective of Chinese or non-Chinese, which was consistent with the meta-analysis conducted by [@B39].

A previous NMA ([@B34]) including 24 RCTs and 6,188 patients showed no significant difference for the efficacy and tolerance between the ordinary doses of different PPIs, which was mostly consistent with our study. However, we included more RCTs (62) and participants (10,339) to make the conclusion of NMA more robust. In addition, in order to perform the pharmacoeconomic analysis, our study only included the standard dose of PPIs rather than LAN (15 mg/day or 60 mg/day) or OME (40 mg/day).

The cost-effectiveness analysis indicated that ILA did not dominate OME, which was inconsistent with the previous study conducted by [@B85]. This could be attributed to the different cost of OME applied in the model: The cost of OME in Xuan's study was set as 16 yuan/day (\$2.5456/day) exceeding the upper limit value in our study. The price of OME was reduced greatly because of greater competition and supply of OME in the domestic market. The data of drug cost in our study was from the National Health and Family Planning Commission of the People's Republic of China and had better representativeness.

There are several limitations in this study. We only included RCTs in this review and were therefore underpowered to find rare AEs related to the medications, as the sample size was relatively small and the follow-up time was indeed short. On the other hand, some included RCTs, especially those from China had poor methodological quality, but results and interpretation did not change when these trials were excluded from the analyses. Due to few trials reporting the results of patients with CYP2C19 genotype, our study did not analyze this genotype stratification.

Conclusion
==========

This study suggests that the efficacy and tolerance of different PPIs are similar in the initial non-eradication treatment of DU, but PAN (40 mg/day) seems to be the most cost-effective choice in China. More RCTs are warranted to compare the efficacy, long term safety, and cost-effectiveness of different PPIs across different CYP2C19 genotypes.
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